6. Dosage unit according to any one of the preceding claims, wherein the estetrol particles have a volume median diameter of 3-35 μm.

7. Dosage unit according to any one of the preceding claims, wherein the dosage unit contains 50-99.9 wt.% of water-soluble carbohydrate selected from maltose, fructose, sucrose, lactose, glucose, galactose, trehalose, xylitol, sorbitol, erythritol, maltitol, mannitol, isomalt and combinations thereof.

8. Dosage unit according to claim 7, wherein the dosage unit contains at least 20 wt.% mannitol.

9. Dosage unit according to any one of the preceding claims, wherein the dosage unit contains 0.1-20 wt.% of a disintegrating agent selected from modified starches, crosslinked polyvinylpyrrolidone, crosslinked carmellose and combinations thereof.

10. Use of an estetrol component for the manufacture of a medicament in the form of a solid dosage unit according to any one of claims 1 to 9, for medical treatment or for female hormone replacement therapy, wherein said solid dosage unit is to be administered sublingually, buccally or sublabially.

11. The use according to claim 10, wherein said solid dosage unit is to be administered once daily during a period of at least 1 week.

12. A method of female contraception, said method comprising sublingual, buccal or sublabial administration of a dosage unit according to any one of claims 1-9.

13. Method according to claim 12, said method comprising once daily administration during a period of at least 1 week.

14. A process of preparing a solid dosage unit according to any one of the preceding claims, said process comprising the steps of:
    - providing estetrol particles containing at least 80 wt.% of an estetrol component selected from estetrol, estetrol esters and combinations thereof and having a volume median diameter of 2 μm to 50 μm;
    - mixing the estetrol particles with one or more granulation excipients to produce a granulation mixture;
    - mixing the granulation mixture with a granulation liquid to produce estetrol-containing granules, said granulation liquid containing at least 60 wt.% of liquid solvent;
    - removing liquid solvent from the estetrol-containing granules to produce dry estetrol-containing granules;
    - optionally mixing the dry granules with one or more tabletting excipients; and
    - forming the dry granules or the mixture of the dry granules and the one or more tabletting excipients into a solid dosage unit.

15. Process according to claim 14, wherein the estetrol particles have a volume median diameter of 3-35 μm.

16. Process according to claim 14 or 15, wherein the granulation mixture contains 0.1-20 wt.% of a disintegrating agent selected from modified starches, crosslinked PVP, crosslinked carmellose and combinations thereof.

17. Process according to any one of claims 14-16, wherein the granulation mixture is produced by combining the estetrol particles with the one or more granulation excipients in a weight ratio that is in the range of 1:4 to 1:1,000.

18. Process according to any one claims 14-17, wherein the estetrol-containing granules are produced by mixing the granulation mixture with the granulation liquid in a weight ratio that is in the range of 0.5:1 to 20:1.